AAP
NAMS icon

Arax Advisory Partners’s NewAmsterdam Pharma NAMS Stock Holding History

Arax Advisory Partners’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.03K Buy
+178
New +$5.87K ﹤0.01% 4544
2025
Q4 		– Sell
-174
Closed -$4.95K – 4379
2025
Q3 		$4.95K Buy
+174
New +$4.17K ﹤0.01% 2876

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Arax Advisory Partners's NAMS Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in NewAmsterdam Pharma (NAMS) in Q2 2026: 178 shares worth $6.03K. The stake represents ﹤0.01% of the portfolio and ranks #4544 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in NAMS as recently as Q3 2025.

Arax Advisory Partners first reported a position in NAMS in Q3 2025 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Arax Advisory Partners held 178 shares of NewAmsterdam Pharma worth $6.03K as of Q2 2026.
  • NewAmsterdam Pharma was a new Arax Advisory Partners position in Q2 2026.
  • NewAmsterdam Pharma made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4544 holding.
  • Arax Advisory Partners first reported a position in NewAmsterdam Pharma in Q3 2025 and has held it in 2 quarters since.
  • 195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.